Your browser doesn't support javascript.
loading
Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy.
Lee, Chee Khoon; Asher, Rebecca; Friedlander, Michael; Gebski, Val; Gonzalez-Martin, Antonio; Lortholary, Alain; Lesoin, Anne; Kurzeder, Christian; Largillier, Remy; Hilpert, Felix; Hardy-Bessard, Anne-Claire; Kaminsky, Marie-Christine; Poveda, Andres; Pujade-Lauraine, Eric.
Afiliación
  • Lee CK; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia. Electronic address: chee.lee@ctc.usyd.edu.au.
  • Asher R; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Friedlander M; Medical Oncology, Prince of Wales Hospital, Sydney, Australia.
  • Gebski V; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia.
  • Gonzalez-Martin A; Grupo Español de Investigación en Cáncer de Ovario (GEICO) and MD Anderson Cancer Center Spain, Madrid, Spain; Clínica Universidad de Navarra, Madrid, Spain.
  • Lortholary A; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO) and Medical Oncology, Hôpital Privé du Confluent S.A.S., Nantes, France.
  • Lesoin A; GINECO and Medical Oncology, Centre Oscar Lambret, Lille, France.
  • Kurzeder C; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and Dept. of Gynecology & Gynecologic Oncology, Klinikum Essen Mitte, Essen, Germany.
  • Largillier R; Centre Azuréen de Cancérologie, Mougins, France.
  • Hilpert F; AGO and Dept. of Gynecology and Obstetrics, University Hospital Kiel, Kiel, Germany; Mammazentrum am Krankenhaus Jerusalem, Hamburg, Germany.
  • Hardy-Bessard AC; GINECO and Medical Oncology, Centre Armoricain d'Oncologie, CARIO, Plérins sur mer, France.
  • Kaminsky MC; GINECO and Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-Lès-Nancy, France.
  • Poveda A; GEICO and Instituto Valenciano de Oncología, Valencia, Spain.
  • Pujade-Lauraine E; ARCAGY-GINECO.
Eur J Cancer ; 117: 99-106, 2019 08.
Article en En | MEDLINE | ID: mdl-31279306
BACKGROUND: Platinum-resistant ovarian cancer (PROC) is associated with a variable prognosis and unpredictable survival times. We have developed and validated a prognostic nomogram with the objective of improving the prediction of overall survival (OS) in patients treated with chemotherapy. METHODS: The nomogram was developed using data from a training cohort of patients from two trials, including the chemotherapy-only arm in AURELIA and all randomised patients in CARTAXHY. Multivariable proportional hazards models were generated based on pretreatment characteristics to develop a nomogram that classifies patients based on OS. We subsequently assessed the performance of the nomogram in terms of discrimination and calibration in independent validation patient cohorts: PENELOPE and the bevacizumab-chemotherapy arm of AURELIA. RESULTS: The nomogram included six significant OS predictors, in order of importance: performance status, ascites, size of the largest tumour, CA-125, platinum-free interval and primary platinum resistance (C-statistic 0.69). In the training cohort, the median OS in the good, intermediate and poor prognosis groups was 25.3, 15.2 and 7.4 months, respectively. In the PENELOPE validation cohort (C-statistic 0.59), the median OS in the good, intermediate and poor prognosis groups was 18.5, 10.3 and 5.8 months, respectively. In the AURELIA bevacizumab-chemotherapy validation cohort (C-statistic 0.67), the median OS in good, intermediate and poor prognosis groups was 26.7, 13.8 and 10.0 months, respectively. CONCLUSIONS: This nomogram with six pretreatment characteristics allows prediction of OS in PROC and could be used for stratification of patients in clinical trials as well as for counselling patients about prognosis.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Protocolos de Quimioterapia Combinada Antineoplásica / Resistencia a Antineoplásicos / Nomogramas Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Protocolos de Quimioterapia Combinada Antineoplásica / Resistencia a Antineoplásicos / Nomogramas Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido